Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.

[1]  S. Rajagopalan,et al.  An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. , 2013, Atherosclerosis.

[2]  S. Frontoni,et al.  Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  A. Miyazaki,et al.  Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. , 2012, Metabolism: clinical and experimental.

[4]  P. Dandona,et al.  Sitagliptin exerts an antinflammatory action. , 2012, The Journal of clinical endocrinology and metabolism.

[5]  S. Ha,et al.  Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes , 2012, Diabetologia.

[6]  G. Paolisso,et al.  Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[7]  N. Marx,et al.  Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe−/− mice , 2012, Diabetologia.

[8]  P. Dandona,et al.  Exenatide exerts a potent antiinflammatory effect. , 2012, The Journal of clinical endocrinology and metabolism.

[9]  S. Rajagopalan,et al.  Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis , 2011, Circulation.

[10]  G. Muscogiuri,et al.  The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. , 2011, Current diabetes reviews.

[11]  Pratik Choudhary,et al.  Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. , 2011, Diabetes technology & therapeutics.

[12]  Paola Palazzo,et al.  Impact of Glycemic and Blood Pressure Variability on Surrogate Measures of Cardiovascular Outcomes in Type 2 Diabetic Patients , 2011, Diabetes Care.

[13]  Z. Li,et al.  O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .

[14]  S. Buscemi,et al.  Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[15]  A. Ceriello.  Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[16]  Yao-min Hu,et al.  Postchallenge plasma glucose excursions, carotid intima-media thickness, and risk factors for atherosclerosis in Chinese population with type 2 diabetes. , 2010, Atherosclerosis.

[17]  C. Jenkinson,et al.  Proteomics Reveals Novel Oxidative and Glycolytic Mechanisms in Type 1 Diabetic Patients' Skin Which Are Normalized by Kidney-Pancreas Transplantation , 2010, PloS one.

[18]  D. Drucker,et al.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice , 2010, Diabetologia.

[19]  A. Csordás,et al.  Rapid ‘glycaemic swings’ induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus , 2009, Diabetologia.

[20]  R. Testa,et al.  Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients , 2008, Diabetes.

[21]  D. Drucker,et al.  Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice , 2007, Diabetes.

[22]  J. DeVries,et al.  Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes , 2007, Diabetologia.

[23]  H. Lapinski,et al.  Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? , 2007, Diabetes & metabolism.

[24]  C. Furberg,et al.  B-Mode Ultrasound: A Noninvasive Method for Assessing Atherosclerosis , 2007 .

[25]  S. Udagawa,et al.  Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes , 2006, Neuroscience Research.

[26]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[27]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[28]  Antonio Ceriello,et al.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. , 2003, Diabetes.

[29]  A. Ceriello,et al.  Role of hyperglycemia in nitrotyrosine postprandial generation. , 2002, Diabetes care.

[30]  M. Hanefeld,et al.  Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. , 2000, Diabetes care.

[31]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[32]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[33]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[34]  F. Folli,et al.  Deranged platelet calcium homeostasis in diabetic patients with end-stage renal failure: A possible link to increased cardiovascular mortality? , 1996, Diabetes Care.

[35]  F. Folli,et al.  Platelet calcium homeostasis is abnormal in patients with severe arteriosclerosis. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[36]  G. Berglund,et al.  Ultrasound-determined intima-media thickness and atherosclerosis. Direct and indirect validation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.